Indian Pharmaceutical Sector Faces Challenges Amid US Market Decline
Pharma cos brace for soft Q4; US drag persists; domestic growth cushions
business-standard
Image: business-standard
The Indian pharmaceutical sector is projected to experience muted growth in Q4 FY26, primarily due to the decline in US sales linked to the loss of exclusivity for Revlimid. Despite this, domestic sales are expected to grow robustly, providing a cushion against international challenges.
- 01Q4 FY26 growth in the Indian pharmaceutical sector is expected to be limited to 7% year-on-year.
- 02US sales are projected to decline by 5% quarter-on-quarter due to the loss of Revlimid sales.
- 03Domestic sales are anticipated to grow by 12% year-on-year, driven by strong demand in chronic therapies.
- 04The ongoing geopolitical situation in the Middle East may impact logistics and costs.
- 05Analysts recommend companies like Sun Pharma, Torrent Pharma, and Lupin as preferred investments.
Advertisement
In-Article Ad
The Indian pharmaceutical sector is expected to report a 7% year-on-year growth in Q4 FY26, hindered by the 'gRevlimid cliff' in the United States, which will notably affect companies like Dr Reddy’s Laboratories and Cipla. Despite this, the domestic market is projected to grow 12% year-on-year, supported by robust demand for chronic therapies and the anticipated launch of generic Semaglutide. Analysts from Kotak Institutional Equities and PL Capital highlight that while US sales for the sector may decline 5% quarter-on-quarter, the underlying business remains stable, particularly for firms with niche portfolios. However, the geopolitical instability in the Middle East poses risks to logistics and costs, potentially impacting revenues. Preferred investment picks include Sun Pharma, Torrent Pharma, and Lupin, as the sector looks to stabilize amidst these challenges.
Advertisement
In-Article Ad
The strong domestic growth provides stability for the Indian pharmaceutical sector, benefiting local companies and consumers reliant on these products.
Advertisement
In-Article Ad
Reader Poll
How do you view the future of the Indian pharmaceutical sector in light of current challenges?
Connecting to poll...
Read the original article
Visit the source for the complete story.